chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Musculoskeletal stiffness, Pruritus, Skin warm, Vaccination site rash
Clinical narrative: On 3/29/21 left arm felt warm, hard, itchy. Noticeable rash 4" around site of injection.; Left arm felt warm, hard, itchy. Noticeable rash 4 around site of injection.; Left arm felt warm, hard, itchy. Noticeable rash 4 around site of injection.; Left arm felt warm, hard, itchy. Noticeable rash 4 around site of injection.; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 26Mar2021 at 12:30 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient was not allergic to medications, food, or other products. Concomitant medications included progesterone (MANUFACTURER UNKNOWN) and unspecified vitamins (MANUFACTURER UNKNOWN). The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 05Mar2021 at 15:15 as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 29Mar2021 at 10:00, the patient's left arm felt warm, hard, and itchy. On the same day, noticeable rash (reported as rash 4) was there around site of injection. Therapeutic measures were taken as a result of events and included treatment with topical analgesic and skin protectant. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events left arm felt warm, hard, itchy, and noticeable rash around site of injection was recovering/resolving.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Peripheral swelling
Clinical narrative: left armpit swelling of gland.; This is a spontaneous report from a non-contactable consumer, the patient. A 43-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the arm left on an unknown date at 14:45 (at the age of 43-year-old) and the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration on an unknown date in 2021 as a single dose for COVID-19 immunization. Medical history was not reported. The patient received unspecified medication within two weeks of vaccination. Patient was allergic to ibuprofen (MANUFACTURER UNKNOWN) from an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Mar2021 the patient experienced left armpit swelling of gland. Event happened about 5 days after the first dose and the next morning after the 2nd dose. The first one went away after about 3 days. The patient did not receive any treatment for the event. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event left armpit swelling of gland was recovered.   No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Constant ringing of the ears; This is a spontaneous report from a contactable other healthcare professional, the patient. A 58-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Er8730) via an unspecified route of administration in the left arm on 28Mar2021 at 09:45 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and hyperthyroidism. The patient had a history of allergy to sulfur. Concomitant medications included amlodipine (MANUFACTURER UNKNOWN), venlafaxine (MANUFACTURER UNKNOWN), levothyroxine (MANUFACTURER UNKNOWN) and lansoprazole (MANUFACTURER UNKNOWN); all from unknown date for unknown indication. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 28Mar2021 at 19:00, the patient experienced constant ringing of the ears. The patient did not receive any treatment for the reported event. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event constant ringing of the ears was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia, Headache, Nausea, Pain
Clinical narrative: Severe body aches; Nausea; Severe headache; Food tastes weird/bitter; This is a spontaneous report from a non-contactable consumer, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 29Mar2021 at 10:00 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included HX breast cancer (remission 3y), fibromyalgia, migraine and gastroesophageal reflux disease (GERD). The patient had no known allergies to medications, food or other products. The patient had no concomitant medications. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient had not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 29Mar2021 at 13:00, the patient experienced severe body aches, nausea, severe headache and food tastes weird/bitter. The patient did not receive any treatment for the events. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events general body pain, nausea, headache and taste bitter were recovering at the time of this report.   No follow-up attempts are possible; information about lot number cannot be obtained.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Paraesthesia
Clinical narrative: I feel like pins and needles are all over my body; Tingling sensation; This is a spontaneous report from a non-contactable consumer, the patient.  A 26-year-old female patient received the unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 29Mar2021 (at the age of 26-year-old) as a single dose for COVID-19 immunisation. Medical history included shingles 3 years ago. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 29Mar2021, the patient experienced tingling sensation that started immediately after vaccination and felt like pins and needles are all over the body. The event resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the event. The clinical outcome of the events pins and needles and tingling sensation was not recovered at the time of the report.  No follow-up attempts are needed; information about the lot number cannot be obtained.
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Ears ringing; This is a spontaneous report from a non-contactable consumer, the patient. A 49-year-old male patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration on an unknown date (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. On an unknown date, the patient experienced ears ringing. The clinical outcome of the event ears ringing was unknown at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 90.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue
Clinical narrative: extreme fatigue; This is a spontaneous report from a contactable consumer, the patient. A 90-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6202), via an unspecified route of administration in the right arm on 04Mar2021 at 13:30 (at the age of 90-years-old) as a single dose for COVID-19 immunisation. Medical history included glaucoma. Concomitant medications included timolol maleate, dorzolamide hydrochloride (COSOPT), tafluprost (ZIOPTAN), losartan (MANUFACTURER UNKNOWN), sertraline hydrochloride (ZOLOFT), simvastatin (ZOCOR) and vitamin d (MANUFACTURER UNKNOWN); all from unknown date for unknown indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EM9810), via an unspecified route of administration in the right arm on 11Feb2021 at 02:30 (at the age of 90-years old) as a single dose for COVID-19 immunisation and betahistine mesilate (DARVON) and indometacin (INDOCIN) on an unknown date for unspecified indication and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 06Mar2021, the patient experienced extreme fatigue since the second dose. The patient did not receive any treatment for the reported event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of extreme fatigue was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Fatigue, Pyrexia
Clinical narrative: Fever; chills; fatigue; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old male patient received the unknown dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE; Lot number; unknown) via an unspecified route of administration on 26Mar2021 at 12:45 (at the age of 38 years) as single dose for COVID-19 immunisation. Medical history included sleep apnea and COVID-19. The patient did not receive any other medications within 2 weeks of vaccination. The patient had no known allergies. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Since the vaccination, patient had not tested for COVID-19. On 26Mar2021 at 20:00, patient experienced event fever, chills and fatigue. The patient did not receive any treatment for the adverse event. The clinical outcome of the events fever, chills and fatigue was recovered on an unknown date in Mar2021.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Menstrual disorder, Pain in extremity
Clinical narrative: Sore Arm; Early menstruation; fatigue; chills; This is a spontaneous report from a contactable other healthcare professional, the patient. A 27-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 25Mar2021 at 18:30 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient did not have allergy to any medications, food, or other products. Concomitant medications included vitamin (MANUFACTURER UNKNOWN), valaciclovir hydrochloride (VALTREX) and birth control all used for an unknown indication and from an unknown date. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 08:00 the patient experienced sore arm, early menstruation, fatigue and chills. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care.  The patient did not receive any treatment for the events. The clinical outcome of sore arm, early menstruation, fatigue and chills were recovered on an unknown date in Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Heart rate increased, Hot flush, Hyperventilation, Oropharyngeal pain
Clinical narrative: hot flashes; Rapid heartbeat; very deep breathing; Tight sore throat; Post nasal drip; Some coughing; This is a spontaneous report from a non-contactable consumer, the patient. A 63-year-old female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration on 30Mar2021 at 14:15 (at the age of 63-years old) as a single dose for COVID-19 immunisation. Medical history included multiple sclerosis (MS). Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Mar2021, the patient experienced hot flashes, rapid heartbeat, very deep breathing with some coughing, tight sore throat and post nasal drip. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events hot flashes, rapid heartbeat, very deep breathing, some coughing, tight sore throat and post nasal drip. The clinical outcomes of the events hot flashes, rapid heartbeat, very deep breathing, some coughing, tight sore throat and post nasal drip were resolving at the time of the report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Upper-airway cough syndrome
Clinical narrative: hot flashes; Rapid heartbeat; very deep breathing; Tight sore throat; Post nasal drip; Some coughing; This is a spontaneous report from a non-contactable consumer, the patient. A 63-year-old female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration on 30Mar2021 at 14:15 (at the age of 63-years old) as a single dose for COVID-19 immunisation. Medical history included multiple sclerosis (MS). Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Mar2021, the patient experienced hot flashes, rapid heartbeat, very deep breathing with some coughing, tight sore throat and post nasal drip. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events hot flashes, rapid heartbeat, very deep breathing, some coughing, tight sore throat and post nasal drip. The clinical outcomes of the events hot flashes, rapid heartbeat, very deep breathing, some coughing, tight sore throat and post nasal drip were resolving at the time of the report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Influenza, Mass
Clinical narrative: flu for two days; Lump in clavicle; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 26Mar2021 at 16:30 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included high cholesterol. The patient did not have any allergies to food, medications, or other products. Concomitant medications included ubidecarenone (COQ10) and unspecified statin for unknown indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the right arm on 05Mar2021 at 15:30 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 28Mar2021, the patient had flu for two days and lump in clavicle. The adverse events resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the events flu for two days and lump in clavicle. The clinical outcomes of the events flu for two days and lump in clavicle were not resolved at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Hyperhidrosis, Lethargy, Pain
Clinical narrative: Body aches.; sweating; chills; lethargy; headache; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955), via an unspecified route of administration in the left arm on 29Mar2021 at 12:45 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no known allergies to medications, food, or other products. Concomitant medications included rosuvastatin calcium (CRESTOR), guanfacine (MANUFACTURER UNKNOWN) and multivitamin (MANUFACTURER UNKNOWN) for unknown indication from unknown dates. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient had not been diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 29Mar2021 at 16:30, the patient experienced body aches, sweating, chills, lethargy and headache. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures and treatments were not taken as a result of the adverse events. The clinical outcome of the events body aches, sweating, chills, lethargy and headache was not recovered at the time of this report.  No follow-up attempts are possible. No further information is expected.
Sex: F
Vaccine: PNC13
Symptoms: Dyspnoea, Throat tightness
Clinical narrative: throat closed up; couldn't breathe; This is a spontaneous report received from a contactable consumer (patient) via medical information Team.  A 21-years-old female patient received pneumococcal 13-val conj vac (dipht crm197 protein) (PREVNAR 13, Solution for injection in pre-filled syringe, Batch/Lot number: Unknown, Expiration date: unknown), via an unspecified route of administration on an unspecified date as dose number unknown single for immunisation. The patient medical history and concomitant medications were not reported. On an unknown date, the patient experienced throat closed up and she couldn't breathe. She wanted to know if she was eligible for the 1st dose of the Pfizer Covid vaccine with a past reaction to Prevnar. Outcome of the events was unknown.  No follow-up attempts are needed. No further information expected.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Diarrhoea, Headache, Pain, Pyrexia
Clinical narrative: slight fever; headache; body aches; diarrhea; This is a spontaneous report from a non-contactable consumer, the patient. A 48-years-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727), via an unspecified route of administration in left arm on 29Mar2021 at 11:45 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high and central sleep apnea syndrome. The patient did not have a history of allergies to any food products, medications or others. Concomitant medications included losartan (MANUFACTURER UNKNOWN), escitalopram oxalate (LEXAPRO), atorvastatin (MANUFACTURER UNKNOWN) and amlodipine (MANUFACTURER UNKNOWN) for an unknown indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206), via an unspecified route of administration in left arm on 08Mar2021 at 10:45 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021 at 06:00, the patient experienced flu-like symptoms such as slight fever, headache, body aches and diarrhea. The patient did not receive any treatment for the reported events. The adverse event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event slight fever, headache, body aches and diarrhea was resolving.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia
Clinical narrative: Novocaine like numbness. Started at injection site up to ear, jaw then within hours whole body numb.; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730), via an unspecified route of administration in the right arm on 24Mar2021 at 16:30 (at the age of 53-years-old), as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient did not have any allergies to medications, food, or other products. Concomitant medications included acetylsalicylic acid (ASPIRIN) for an unknown indication from an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Mar2021 at 17:00, the patient experienced novocaine like numbness started at injection site up to ear, jaw then within hours whole body numb and by next day it was better. The patient did not receive any treatment for the event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event body numbness was recovered on an unspecified date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: Headache persisting and worsening despite meds.; This is a spontaneous report from a contactable healthcare professional, the physician. A 61-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an intramuscular route of administration in the left arm on 16Mar2021 at 14:45 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and thyroid disease. The patient had no known allergies. Concomitant medication included losartan (MANUFACTURER UNKNOWN) and levothyroxine sodium (UNITHROID) for an unknown indication. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient had not received any other vaccine within 4 weeks prior to the COVID vaccine. On an unknown date in Mar2021, the patient experienced headache, which was persisting and had worsened despite the medications. The event had resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures taken for the event included nabumetone. The clinical outcome of the event persistent headache was not recovered at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 22.0
Sex: M
Vaccine: COVID19
Symptoms: Cough, Fatigue, Myalgia, Pain, Pain in extremity
Clinical narrative: arm felt sore; muscle aches; fatigue; feeling an itching sensation under myskin around my torso; slight cough; soreness all over; This is a spontaneous report from a contactable consumer, the patient. A 22-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EWOISO) via unspecified route of administration in the right arm on 31Mar2021 at 12:30 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. The patient medical history included asthma. The patient was allergic to any and all molds, molds in food, medications such as penicillin, augmentin, etc. and latex. Concomitant medication included fexofenadine hydrochloride (ALLEGRA), salbutamol (ALBUTEROL), vitamin D (MANUFACTURER UNKNOWN) and multivitamin (MANUFACTURER UNKNOWN) all for an unknown indication and from an unknown date. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 31Mar2021 at 16:00, patient experienced sore arm, muscle aches, fatigue, soreness all over, itching sensation under skin around torso, and a slight cough. The patient did not receive any treatment for the adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events sore arm, muscle aches, fatigue, soreness all over, itching skin, and cough was resolving.    No follow-up attempts are needed. No further information is expected.
Age: 22.0
Sex: M
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: arm felt sore; muscle aches; fatigue; feeling an itching sensation under myskin around my torso; slight cough; soreness all over; This is a spontaneous report from a contactable consumer, the patient. A 22-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EWOISO) via unspecified route of administration in the right arm on 31Mar2021 at 12:30 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. The patient medical history included asthma. The patient was allergic to any and all molds, molds in food, medications such as penicillin, augmentin, etc. and latex. Concomitant medication included fexofenadine hydrochloride (ALLEGRA), salbutamol (ALBUTEROL), vitamin D (MANUFACTURER UNKNOWN) and multivitamin (MANUFACTURER UNKNOWN) all for an unknown indication and from an unknown date. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 31Mar2021 at 16:00, patient experienced sore arm, muscle aches, fatigue, soreness all over, itching sensation under skin around torso, and a slight cough. The patient did not receive any treatment for the adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events sore arm, muscle aches, fatigue, soreness all over, itching skin, and cough was resolving.    No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling abnormal, Headache, Myalgia, Nausea
Clinical narrative: Headache; muscle pain; extreme nausea; brain fog; This is a spontaneous report from a non-contactable consumer, the patient. A 43-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er8735) via an unspecified route of administration on 30Mar2021 at 14:45 (at the age of 43-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 31Mar2021 at 08:00, the patient experienced headache, muscle pain, extreme nausea, and brain fog. The patient did not receive treatment for the reported events. The clinical outcomes of the events headache, muscle pain, extreme nausea, and brain fog were not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Tenderness
Clinical narrative: tenderness in underarm (left side); This is a spontaneous report from a non-contactable consumer, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955) via an unspecified route of administration in the left arm on 26Mar2021 at 12:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history not reported. Concomitant medication included unspecified medication birth control (MANUFACTURER UNKNOWN) on an unknown start date received within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3248) via an unspecified route of administration in the left arm on 05Mar2021 at 13:00 as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021, the patient experienced tenderness in underarm (left side), the patient thought it could possibly be a lymph node. The patient did not receive any treatment for the event.  The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event tenderness in underarm (left side) was resolved on an unknown date in Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Headache, Lethargy, Neck pain, Pain
Clinical narrative: Fever (101); Extreme lethargy; Entire body ached; Headache (forehead)/Persistent sharp ache back of head; Persistent sharp ache back of neck; This is a spontaneous report received from a non-contactable consumer, the patient. A 55-years-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via an unspecified route of administration in his left arm on 24Mar2021 (at the age of 55-years-old), as a single dose for COVID-19 immunisation. The patient's medical history included hypothyroid and obese. Concomitant medications and medications within 2 weeks of vaccination included Multivitamin (MANUFACTURER UNKNOWN), Levothyroxine (MANUFACTURER UNKNOWN), Fish oil (MANUFACTURER UNKNOWN) and Magnesium (MANUFACTURER UNKNOWN) from an unknown date for unknown indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6198) via an unspecified route of administration in his left arm on 04Mar2021 at 13:30 (at the age of 55-years-old), as a single dose for COVID-19 immunisation. The patient did not have a history of allergies to medications, food or other products. The patient had not received other vaccines within 4 weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had not tested for COVID-19. The patient had not diagnosed with COVID-19 prior to vaccination. On 25Mar2021 at 09:00, the patient experienced fever (101), extreme lethargy, entire body ached, headache (forehead), persistent sharp ache back of head and neck, no loss of appetite, stayed in bed entire day on 25Mar and woke the following day and felt fine on 26Mar. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. On an unspecified date, the patient underwent body temperature recording and the result was fever 101. The clinical outcomes for the events fever (101), extreme lethargy, entire body ached, headache (forehead), persistent sharp ache back of head and neck was recovered on 26Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Fever (101); Extreme lethargy; Entire body ached; Headache (forehead)/Persistent sharp ache back of head; Persistent sharp ache back of neck; This is a spontaneous report received from a non-contactable consumer, the patient. A 55-years-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via an unspecified route of administration in his left arm on 24Mar2021 (at the age of 55-years-old), as a single dose for COVID-19 immunisation. The patient's medical history included hypothyroid and obese. Concomitant medications and medications within 2 weeks of vaccination included Multivitamin (MANUFACTURER UNKNOWN), Levothyroxine (MANUFACTURER UNKNOWN), Fish oil (MANUFACTURER UNKNOWN) and Magnesium (MANUFACTURER UNKNOWN) from an unknown date for unknown indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6198) via an unspecified route of administration in his left arm on 04Mar2021 at 13:30 (at the age of 55-years-old), as a single dose for COVID-19 immunisation. The patient did not have a history of allergies to medications, food or other products. The patient had not received other vaccines within 4 weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had not tested for COVID-19. The patient had not diagnosed with COVID-19 prior to vaccination. On 25Mar2021 at 09:00, the patient experienced fever (101), extreme lethargy, entire body ached, headache (forehead), persistent sharp ache back of head and neck, no loss of appetite, stayed in bed entire day on 25Mar and woke the following day and felt fine on 26Mar. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. On an unspecified date, the patient underwent body temperature recording and the result was fever 101. The clinical outcomes for the events fever (101), extreme lethargy, entire body ached, headache (forehead), persistent sharp ache back of head and neck was recovered on 26Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Urticaria
Clinical narrative: big red itchy hive appeared near the injection site.; This is a spontaneous report received from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Er8727) via an unspecified route of administration in the right arm on 20Mar2021 at 15:30 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Patient had allergies to shellfish, mushrooms, cats and seasonal allergies. Concomitant medication included daily vitamins (MANUFACTURER UNKNOWN). Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient had not received any other vaccine within 4 weeks prior to the COVID vaccine. On 20Mar2021, it was reported as "within few minutes after receiving my first dose, a big red itchy hive appeared near the injection site. Should I get the second dose?". The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measure was taken as a result of the event. The clinical outcome of the event big red itchy hive was recovered on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Allergy test, Pruritus, Urticaria
Clinical narrative: big red itchy hive appeared near the injection site.; This is a spontaneous report received from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Er8727) via an unspecified route of administration in the right arm on 20Mar2021 at 15:30 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Patient had allergies to shellfish, mushrooms, cats and seasonal allergies. Concomitant medication included daily vitamins (MANUFACTURER UNKNOWN). Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient had not received any other vaccine within 4 weeks prior to the COVID vaccine. On 20Mar2021, it was reported as "within few minutes after receiving my first dose, a big red itchy hive appeared near the injection site. Should I get the second dose?". The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measure was taken as a result of the event. The clinical outcome of the event big red itchy hive was recovered on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Dizziness, Fatigue, Nausea, Pain
Clinical narrative: body aches; Fatigue; Joint ache; Nausea; dizziness; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: ER8733) via an unspecified route of administration in the left arm on 30Mar2021 at 17:30 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism. Concomitant medications were not reported. On 16Mar2021, the patient received varicella zoster vaccine vgE cho ( SHINGRIX ) vaccine 4 weeks prior to the COVID vaccine. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. On an unknown date the patient underwent nasal Swab test and the result was tested negative. On 31Mar2021 at 10:00, the patient experienced fatigue, body and joint aches, nausea and dizziness. No therapeutic measures were taken as the result of adverse events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fatigue, body and joint aches, nausea and dizziness were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test
Clinical narrative: body aches; Fatigue; Joint ache; Nausea; dizziness; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: ER8733) via an unspecified route of administration in the left arm on 30Mar2021 at 17:30 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism. Concomitant medications were not reported. On 16Mar2021, the patient received varicella zoster vaccine vgE cho ( SHINGRIX ) vaccine 4 weeks prior to the COVID vaccine. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. On an unknown date the patient underwent nasal Swab test and the result was tested negative. On 31Mar2021 at 10:00, the patient experienced fatigue, body and joint aches, nausea and dizziness. No therapeutic measures were taken as the result of adverse events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fatigue, body and joint aches, nausea and dizziness were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoglycaemia
Clinical narrative: Hypoglycemia; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the right arm on 16Mar2021 at 14:15 (at the age of 68-year-old) as a single dose for COVID-19 immunisation. Medical history was reported as blood pressure. The patient was allergic to unspecified medications, food or other products. The patient received unspecified medications within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Mar2021, the patient experienced hypoglycemia. Therapeutic measures were taken as a result of hypoglycemia which included treatment with sugar-chocolate. The adverse event did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the event hypoglycemia was recovered with sequelae on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Headache, Hyperhidrosis, Oropharyngeal pain
Clinical narrative: Headache; Dizziness; Fatigue; Sore throat; Runny nose; Pain at injection site; Body Aches; Fever; Sweating; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955), via an unspecified route of administration in the arm left on 25Mar2021 at 16:00 (at the age of 35-years-old), as a single dose for COVID-19 immunisation. Medical history included high blood pressure, hypothyroidism and egg allergy.  The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 00:00, the patient experienced headache, dizziness, fatigue, sore throat, runny nose, pain at injection site, body aches, fever and sweating. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient was treated for the headache, dizziness, fatigue, sore throat, runny nose, pain at injection site, body aches, fever and sweating with over the counter (OTC) medications. The clinical outcome of the events headache, dizziness, fatigue, sore throat, runny nose, pain at injection site, body aches, fever and sweating were not resolved at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia, Rhinorrhoea, Vaccination site pain
Clinical narrative: Headache; Dizziness; Fatigue; Sore throat; Runny nose; Pain at injection site; Body Aches; Fever; Sweating; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955), via an unspecified route of administration in the arm left on 25Mar2021 at 16:00 (at the age of 35-years-old), as a single dose for COVID-19 immunisation. Medical history included high blood pressure, hypothyroidism and egg allergy.  The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 00:00, the patient experienced headache, dizziness, fatigue, sore throat, runny nose, pain at injection site, body aches, fever and sweating. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient was treated for the headache, dizziness, fatigue, sore throat, runny nose, pain at injection site, body aches, fever and sweating with over the counter (OTC) medications. The clinical outcome of the events headache, dizziness, fatigue, sore throat, runny nose, pain at injection site, body aches, fever and sweating were not resolved at the time of reporting.   No follow-up attempts are needed. No further information is expected.